January 2017

New Product - Movapo PFS

Movapo PFS (apomorphine hydrochloride) is a directly acting dopamine receptor agonist, structurally related to dopamine. Movapo PFS is indicated to reduce the number and severity of ‘off’ phases in patients with Parkinson’s disease severely disabled by motor fluctuations refractory to conventional therapy. Initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. Conventional therapy should be continued during ‘on’ phases. Movapo PFS is contraindicated in patients with a known hypersensitivity or allergy to apomorphine, morphine or chemically related products. Movapo PFS should not be administered to patients with pre-existing neuropsychiatric problems or dementias due to either a pathological processes, e.g. Alzheimer’s disease, or to patients whose ‘on’ response to L-dopa is marred by severe dyskinesia, hypotonia or psychotoxicity. Movapo PFS is also contraindicated in patients with inadequate renal or liver function, unstable coronary vascular disease, cerebrovascular disease, respiratory depression or CNS depression. Movapo PFS is contraindicated in patients with a known hypersensitivity to sodium metabisulfite. Movapo PFS is available as a prefilled syringe solution for subcutaneous infusion containing 50 mg/10 mL (10 mL syringe) apomorphine hydrochloride in packs of 5’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629